Form 4: Sage Therapeutics COO Christopher Benecchi Reports Stock Transactions Following PSU Vesting

Christopher Benecchi, Chief Operating Officer of Sage Therapeutics, reports the acquisition of shares through vested Performance Restricted Stock Units (PSUs) and subsequent disposal of shares to cover tax obligations.

Summary

• Christopher Benecchi, the Chief Operating Officer of Sage Therapeutics, reported transactions involving the company's common stock on April 10, 2025.
• These transactions include the acquisition of 3,255 shares and 2,712 shares of common stock upon the vesting of Performance Restricted Stock Units (PSUs).
• The vesting was triggered by the achievement of certain milestones related to PSUs granted on February 11, 2022, and June 16, 2022, respectively.
• Benecchi also disposed of 793 shares and 661 shares to satisfy tax obligations at a price of $6.91 per share.
• Following these transactions, Benecchi beneficially owns 48,428 shares of Sage Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation. The vesting of PSUs suggests the achievement of certain performance milestones, which is mildly positive.

Positives

• The vesting of PSUs indicates that Sage Therapeutics has achieved certain performance milestones.

Industry Context

Tracking insider transactions provides insights into management's perspective on the company's performance and future prospects, which is a common practice in the biopharmaceutical industry.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.

Key Dates

Keywords

Form 4, Sage Therapeutics, Christopher Benecchi, PSU, Stock Options, Beneficial Ownership, Officer Transactions